Many cancer drugs cause aching joints or muscles: hormone tablets for breast cancer, paclitaxel, ibrutinib and others. Tell your team rather than putting up with it. Exercise, painkillers, acupuncture or a change of drug or dose may help. On some targeted drugs, muscle pain with weakness or dark urine needs a call to your team straight away.
Joint and muscle symptoms are among the commonest side effects of several unrelated drug groups, and the guidance is thin and differs by drug. The reader's own team's protocol comes first.
Aromatase inhibitors. In the US letrozole label arthralgia was reported by 25.2% on letrozole against 20.4% on tamoxifen, and in the US exemestane label by 15% against 9%; the duloxetine trial's authors say about half of patients develop bothersome symptoms and 20% to 30% stop treatment early. SIO-ASCO (2022, read as an abstract) says acupuncture should be recommended. The two Cochrane reviews are less confident: the exercise review (seven studies, 400 women) found no clear evidence of benefit for these symptoms but says exercise needs to be part of routine care, and the systemic therapy review (17 studies, 2034 women) could make no definitive recommendation. Single trials: exercise (HOPE; worst joint pain fell by 1.6 points against a 0.2-point rise at 12 months), duloxetine (SWOG S1202, part-funded by Lilly; average pain 0.82 points lower than placebo by 12 weeks, with more side effects) and acupuncture (SWOG S1200; a significant reduction of uncertain clinical importance). After a switch to a second aromatase inhibitor, 38.6% of 83 women stayed on it in one study and 71.5% of 179 at 6 months in another.
Paclitaxel and nab-paclitaxel. Aches come two or three days after a dose and resolve within a few days (US paclitaxel label: 60% of patients, 8% severe; the NCI summary says 10% to 20%, starting after 1 to 2 days and lasting a median of 4 to 5 days). No preventive or treatment standard exists; simple painkillers, then opioids as needed, were used in the cohort study.
Ibrutinib. Two expert papers differ: one favours observation and supportive care for grade 1 to 2, considering a dose reduction when daily activities are affected and holding for grade 3; the other suggests paracetamol or short pulses of prednisone while ibrutinib continues at the full dose, avoiding ibuprofen-type drugs if possible because of bleeding, and holding for up to a week then reducing one level if the pain cannot be tolerated. Both mention a change to another BTK inhibitor.
Imatinib cramps: monitor and correct electrolytes; otherwise symptomatic relief only (ELN 2016).
Creatine kinase. Binimetinib, cobimetinib and avutometinib with defactinib carry rhabdomyolysis warnings with CK monitoring and hold rules. For binimetinib the US and EU documents differ on when to withhold; for cobimetinib they differ mainly on how often to test and on the terms for restarting; no EU document was found for avutometinib with defactinib. They are set out under variants. Encorafenib and vemurafenib joint pain falls under each label's general rule for adverse reactions. Rhabdomyolysis itself, and muscle or joint inflammation from checkpoint inhibitors, are outside this page.
Why: The review that says this is about BTK inhibitors, and it does not list the other causes. No source read states this step for the other drugs on this page, so it is given here for BTK inhibitors only.
“Rule out other causes of arthralgia.”
Why: This is Macmillan's wording for patients on its letrozole page; its pages for the other aromatase inhibitors were not read. Macmillan says the team can give advice and painkillers or other drugs. The duloxetine trial's authors report that 20% to 30% of patients stop these tablets early because they cannot tolerate them, mostly because of joint and muscle symptoms. In the ELPh study 38.6% of 83 women who switched to the other aromatase inhibitor stayed on it, and in the ATOLL study 71.5% of 179 women who moved from anastrozole to letrozole were still taking it at 6 months; neither study had a comparison group.
“If the pain does not get better, tell your doctor or nurse. They may talk to you about changing to a different hormonal drug.”
Why: Macmillan says activity can keep joints flexible and reduce stress on them. The Cochrane review found no clear evidence that exercise helps these symptoms (seven studies, 400 women, very low certainty) and asks for it anyway because of its other benefits. In the HOPE trial of 121 previously inactive women, 150 minutes a week of aerobic exercise with supervised strength training twice a week lowered worst joint pain by 1.6 points at 12 months, against a rise of 0.2 points with usual care.
“Despite these inconclusive findings, exercise still needs to be part of routine care for women with breast cancer.”
Cochrane Database of Systematic Reviews (Roberts et al.) 2020
Why: Only the guideline's abstract was read. It gives one summary grade for four recommendations together, of which this is one, and says the benefit outweighs the risk; the grade printed for this recommendation alone was not seen. In the SWOG S1200 trial, 12 sessions over 6 weeks and then one a week for 6 weeks reduced joint pain more than sham acupuncture or a waiting list at 6 weeks; its authors call the improvement of uncertain clinical importance.
“Among adult patients, acupuncture should be recommended for aromatase inhibitor-related joint pain.”
Journal of Clinical Oncology (Mao et al.) 2022 · intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation
Why: The NHS gives no reason. The duloxetine trial's authors say this pain is usually treated empirically with paracetamol (acetaminophen), anti-inflammatory painkillers or opioids.
“Ask a pharmacist to recommend a suitable painkiller. If the pain does not go away ask your doctor for advice.”
Why: The NHS follows this with the statement that these tablets can make bones weaker, with an increased risk of osteoporosis or bone injuries.
“If you have a sudden attack of pain in a joint ask a doctor for advice urgently.”
Why: The US paclitaxel label says the symptoms were usually transient, came two or three days after a dose and resolved within a few days; 60% of patients had them and 8% had severe symptoms. The NCI summary gives different figures: a syndrome of diffuse joint and muscle pain in 10% to 20% of patients, starting 1 to 2 days after the infusion and lasting a median of 4 to 5 days. The quote is from the patient counselling section of the US nab-paclitaxel label; the EU documents were not read.
“Explain to patients that alopecia, fatigue/asthenia, and myalgia/arthralgia occur frequently with ABRAXANE.”
Abraxis BioScience (Bristol Myers Squibb), on DailyMed (US National Library of Medicine) 2022
Why: No treatment is established as standard. In the NCCTG cohort study people were told to use paracetamol or anti-inflammatory painkillers first, with opioids as needed; non-prescription medicines were used by 30% to 41% of patients each week and opioids by 12% to 20%. The NCI summary says steroids may reduce the tendency to develop these aches.
“You might feel some pain from your muscles and joints. Speak to your doctor or nurse about what painkillers you can take to help with this.”
Why: This is the authors' own practice. They report joint and muscle pain in 11% to 36% of people on ibrutinib and say the migratory joint pains can be debilitating. In the Pennsylvania cohort, 36% of 214 patients developed it and 62% of those with grade 3 pain ultimately stopped ibrutinib.
“When grade 1-2, we favor observation and supportive care. Consider dosage reduction when symptoms affect ADLs, with dose holds for grade ≥3 AEs (affecting self-care ADLs) and rechallenge at lower doses if resolution of symptoms.”
Why: The authors give the reason as the risk of bleeding when such painkillers are taken with ibrutinib. The other review says steroids should be a short course at low dose because of the risk of fungal infection, and that anti-inflammatory drugs must be used cautiously.
“When managing ibrutinib-associated arthralgia, the use of anti-inflammatory agents with antiplatelet adverse events, such as ibuprofen, should be avoided if possible secondary to bleeding risk when used concurrently with ibrutinib.”
Why: The hold is to let the symptoms resolve. The authors add that in some cases a change to another BTK inhibitor such as acalabrutinib can lessen or resolve the problem. The US and EU labels have no rule for joint pain; both set a general rule for grade 3 or 4 non-blood side effects, which is to interrupt and restart at a lower dose after recovery.
“If the patient cannot tolerate the arthralgia, then we suggest holding the dose of ibrutinib for up to a week to allow symptoms to resolve and reduction of the dose by 1 dose level (for example, 420 mg to 280 mg).”
Why: The European LeukemiaNet says that, other than symptomatic relief, there is no definitive treatment, and that some patients find relief with drinks containing quinine. It says the cause of the cramps is unknown, although they have been linked with low adjusted calcium levels, and that they interfere with quality of life.
“Serum electrolyte levels should be monitored and corrected, if necessary.”
Why: The label says rhabdomyolysis (muscle breakdown) can occur with cobimetinib. The US binimetinib label asks for the same tests at the same times. How often to test differs by document: the EU cobimetinib and binimetinib documents say monthly (binimetinib for the first 6 months, and as clinically indicated); the US label for avutometinib with defactinib says before each cycle and on day 15 of the first four cycles. The labels of other MEK inhibitors, trametinib and selumetinib among them, were not read.
“Obtain baseline serum CPK and creatinine levels prior to initiating COTELLIC, periodically during treatment, and as clinically indicated. If CPK is elevated, evaluate for signs and symptoms of rhabdomyolysis or other causes.”
Genentech, on DailyMed (US National Library of Medicine) 2026
Why: The label gives no reason beyond its rhabdomyolysis warning. The EU document differs: with symptoms or kidney impairment it acts only from grade 3; for a grade 3 rise without symptoms it keeps the dose and asks that the person is adequately hydrated; and it advises an adequate fluid intake throughout treatment. Both documents leave the encorafenib dose unchanged for a creatine kinase rise.
“Withhold MEKTOVI dose for up to 4 weeks.”
Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2025
Why: The label reports a raised creatine kinase in 75% of patients, grade 3 to 4 in 18%, and rhabdomyolysis in one patient in a clinical trial. If a grade 3 rise improves to grade 1 or less within three weeks the same dose is resumed; after grade 4, a reduced dose. No EU document was found.
“Permanently discontinue AVMAPKI FAKZYNJA CO-PACK for CPK elevation longer than three weeks.”
Verastem, on DailyMed (US National Library of Medicine) 2025
Why: The US Medication Guides say these drugs can cause muscle problems that can be severe; the quote is the binimetinib guide, and the cobimetinib guide uses the same words for muscle aches or pain, muscle spasms and weakness, and dark, reddish urine. The EU binimetinib leaflet says to talk to the doctor immediately about muscle pain, cramps, stiffness, spasm or dark urine, and that muscle breakdown can lead to kidney damage and can be fatal.
“Tell your healthcare provider right away if you develop any of these symptoms:”
Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2025
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No single guideline covers this ground, and the sources disagree in places. For aromatase inhibitor joint pain, the only graded recommendation read is SIO-ASCO 2022 (acupuncture should be recommended; moderate strength), read as an abstract whose one grade covers four recommendations. The Cochrane reviews are more cautious than the single trials they include: no clear evidence of benefit for exercise, which they still want as part of routine care, and no definitive recommendation for any systemic therapy, duloxetine included, although the duloxetine trial (part-funded by Lilly) and the HOPE exercise trial each met their primary end point. Switching to a second aromatase inhibitor rests on two studies without a comparison group, one supported by grants from Pfizer and Novartis. For the aches after paclitaxel, no prevention or treatment is established. For ibrutinib, two expert papers give their own practice and differ on steroids, on anti-inflammatory painkillers and on when to hold. For imatinib cramps the European LeukemiaNet offers electrolyte correction and symptomatic relief only. For a raised creatine kinase the labels are the source, and the US and EU documents differ on the threshold for withholding binimetinib, on the terms for restarting cobimetinib and on how often to test.
Journal of Clinical Oncology (Mao et al.) 2022 · Cochrane Database of Systematic Reviews (Roberts et al.) 2020 · Cochrane Database of Systematic Reviews (Roberts et al.) 2022 · Journal of Clinical Oncology (Henry et al.; supported by the US National Cancer Institute and in part by Lilly USA, the maker of duloxetine) 2018 · Journal of Clinical Oncology (Irwin et al.) 2015 · Journal of Clinical Oncology (Henry et al.; supported by US National Institutes of Health grants and by grants from Pfizer and Novartis Pharma AG, the makers of exemestane and letrozole) 2012 · Breast Cancer Research and Treatment (Briot et al.; funding not stated in the abstract) 2010 · Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from makers of BTK inhibitors) 2020 · Blood (Stephens and Byrd; supported by foundations and the US National Cancer Institute; both authors declare research funding from makers of BTK inhibitors) 2019 · Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 · Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2025 · Pierre Fabre Médicament, on the European Medicines Agency website 2026 · Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche Registration, on the European Medicines Agency website 2025
Where it differs: Duloxetine 30 mg daily for 1 week, then two capsules daily for 11 weeks, then one capsule daily for 1 week, in postmenopausal women with early breast cancer whose average joint pain was 4 or more out of 10 and had developed or worsened since starting an aromatase inhibitor.
Evidence: One randomised, double-blind, placebo-controlled trial (299 enrolled; funded by the US National Cancer Institute and in part by Lilly USA). By 12 weeks average joint pain was 0.82 points lower with duloxetine than with placebo; no difference was seen at week 24, 12 weeks after the full dose ended. Side effects of any grade were more frequent with duloxetine (78% against 50%). The Cochrane review of systemic therapies lists duloxetine among the treatments whose effect did not include a minimal clinically important difference and makes no definitive recommendation for any systemic therapy. No guideline read recommends it for this use.
Journal of Clinical Oncology (Henry et al.; supported by the US National Cancer Institute and in part by Lilly USA, the maker of duloxetine) 2018 · Cochrane Database of Systematic Reviews (Roberts et al.) 2022
Where it differs: After stopping one aromatase inhibitor for intolerable symptoms, starting another: exemestane to letrozole or the reverse after a 2 to 8 week washout (ELPh), or anastrozole to letrozole after 1 month (ATOLL).
Evidence: ELPh (503 women; supported in part by grants from Pfizer and Novartis): 32.4% stopped the first drug within 2 years because of side effects, 24.3% because of musculoskeletal symptoms; of 83 who chose to switch, 38.6% continued the second drug for a median of 13.7 months, and 61.4% stopped it. ATOLL (abstract only; 179 women, not randomised): 71.5% continued letrozole at 6 months and 28.5% stopped because of severe joint pain. Neither study had a group that stayed on the first drug. Macmillan tells patients the team may talk about changing to a different hormonal drug.
Journal of Clinical Oncology (Henry et al.; supported by US National Institutes of Health grants and by grants from Pfizer and Novartis Pharma AG, the makers of exemestane and letrozole) 2012 · Breast Cancer Research and Treatment (Briot et al.; funding not stated in the abstract) 2010 · Macmillan Cancer Support 2025
Where it differs: Lipsky and Lamanna (2020): observation and supportive care at grade 1 to 2, a dose reduction considered when daily activities are affected, a hold at grade 3 or higher; magnesium and quinine-containing tonic water as anecdotal additions; a short course of low-dose steroids and cautious anti-inflammatory drugs for severe pain. Stephens and Byrd (2019): paracetamol or short pulses of prednisone while continuing the full dose, ibuprofen-type drugs avoided if possible (the authors say one can be started once the pain has abated, which they find happens after 6 months or more of treatment), and a hold of up to a week with a one-level dose reduction if the pain cannot be tolerated. Both mention a change to another BTK inhibitor such as acalabrutinib.
Evidence: Expert opinion; Lipsky and Lamanna say the evidence for specific drugs is anecdotal. In the Pennsylvania cohort (Rhodes 2020, 214 patients) a dose reduction alone relieved symptoms in 60% (9 of 15) and a hold alone in 14% (1 of 7), as the results text gives them; the paper's table prints 40% beside the same 1 of 7, and its abstract says holds were the more successful. The authors say supportive measures were not used often enough to evaluate. The US label and the EU product information have no rule for joint pain: for grade 3 or 4 non-blood side effects both interrupt treatment and lower the dose on restarting, but the steps differ (US, for the 420 mg dose: 280 mg after the first occurrence, 140 mg after the second, discontinue after the third; EU, for the 420 mg dose: 420 mg after the first, 280 mg after the second, 140 mg after the third, discontinue after the fourth).
Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from makers of BTK inhibitors) 2020 · Blood (Stephens and Byrd; supported by foundations and the US National Cancer Institute; both authors declare research funding from makers of BTK inhibitors) 2019 · Clinical Lymphoma, Myeloma and Leukemia (Rhodes et al.; supported by a US training grant and a Conquer Cancer Foundation award; several authors declare consultancy or research funding from makers of BTK inhibitors) 2020 · Pharmacyclics and Janssen, on DailyMed (US National Library of Medicine) 2025 · Janssen-Cilag International, on the European Medicines Agency website 2026
Where it differs: Binimetinib, US: withhold for up to 4 weeks for grade 4 without symptoms or any grade with symptoms or kidney impairment; resume reduced at grade 0 to 1; stop for good if not resolved within 4 weeks. Binimetinib, EU: grade 3 without symptoms, keep the dose and ensure hydration; grade 4 without symptoms, withhold until grade 0 or 1; grade 3 or 4 with muscle symptoms or kidney impairment, withhold until grade 0 or 1, then resume reduced if resolved within 4 weeks or stop for good. Cobimetinib, US: withhold for up to 4 weeks for grade 4, or any rise with myalgia; resume at the next lower dose if improved to grade 3 or lower; stop for good if not improved within 4 weeks. Cobimetinib, EU: interrupt for rhabdomyolysis or a symptomatic rise, restart at a dose reduced by 20 mg if clinically indicated once the severity has improved by at least one grade within 4 weeks, and stop for good if it has not; interrupt for grade 4 without symptoms, with the same restart once it is grade 3 or lower within 4 weeks; no change at grade 3 or lower without symptoms once rhabdomyolysis is ruled out. Avutometinib with defactinib, US: withhold at grade 3 or 4, resume at the same dose after grade 3 and a reduced dose after grade 4 if it improves to grade 1 or less within three weeks, stop for good after three weeks or with rhabdomyolysis. Gilteritinib: creatine kinase is part of the blood chemistry checks (US: before starting, at least weekly for the first month, every other week for the second, then monthly; EU: before starting, on day 15 and monthly), with no rule of its own; both documents interrupt for other grade 3 or higher toxicity until it resolves or improves to grade 1. Vimseltinib: neither document has a creatine kinase rule; the EU text says dose interruptions or reductions may be required based on individual safety and tolerability.
Evidence: Regulatory documents. Binimetinib US label: raised creatine kinase in 58% of patients in the COLUMBUS trial, with rhabdomyolysis in 1 patient (0.1%) of 690. Cobimetinib US label: grade 3 or 4 rises in 14% with vemurafenib against 0.5% on vemurafenib alone, first appearing at a median of 16 days. Gilteritinib: muscle or joint pain in 50% of 319 patients, grade 3 or higher in 7% (US label); a raised creatine kinase in 53.9% (EU text). Vimseltinib EU text: a rise was seen in all 66 patients in the phase 1/2 study, is described as consistent with the mechanism of action, and had not led to rhabdomyolysis in clinical studies; a raised creatine kinase led to a dose reduction or interruption in 17%.
Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2025 · Pierre Fabre Médicament, on the European Medicines Agency website 2026 · Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche Registration, on the European Medicines Agency website 2025 · Verastem, on DailyMed (US National Library of Medicine) 2025 · Astellas Pharma US, on DailyMed (US National Library of Medicine) 2026 · Astellas Pharma Europe, on the European Medicines Agency website 2024 · Deciphera Pharmaceuticals, on DailyMed (US National Library of Medicine) 2026 · Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026
Where it differs: Neither drug has a rule written for joint pain. Vemurafenib, US: withhold for an intolerable grade 2 or greater adverse reaction and restart at 720 mg twice daily on recovery to grade 0 to 1 (480 mg after a second appearance). Vemurafenib, EU: the same doses, with the dose kept at grade 1 or tolerable grade 2 and treatment stopped for good at a third occurrence. Encorafenib, US and EU: withhold for up to 4 weeks for recurrent grade 2 or a first grade 3 reaction (the EU text adds intolerable grade 2), resume at a reduced dose if it improves to grade 0 to 1 or baseline, and stop for good if it does not.
Evidence: Regulatory documents. Arthralgia was reported by 53% of patients on vemurafenib in its trial in previously untreated melanoma (US label), and by 44% on encorafenib alone against 26% when given with binimetinib (US label). No management guidance specific to this joint pain was read.
Genentech, on DailyMed (US National Library of Medicine) 2026 · Roche Registration, on the European Medicines Agency website 2025 · Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2026 · Pierre Fabre Médicament, on the European Medicines Agency website 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Acupuncture should be recommended for aromatase inhibitor joint pain “These recommendations are based on an intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation.” | intermediate level of evidence, benefit outweighing risk, and with moderate strength of recommendation | Journal of Clinical Oncology (Mao et al.) 2022 |
| Exercise for aromatase inhibitor musculoskeletal symptoms: no clear evidence of benefit “There was insufficient evidence to assess the use of exercise in the prevention of AIMSS.” | Cochrane review; very low-certainty evidence (GRADE) | Cochrane Database of Systematic Reviews (Roberts et al.) 2020 |
| Systemic therapies for aromatase inhibitor musculoskeletal symptoms: no definitive recommendation “no definitive recommendations for systemic therapies for either prevention or treatment of AIMSS on the basis of this review can be made.” | Cochrane review; very low-certainty evidence (GRADE) | Cochrane Database of Systematic Reviews (Roberts et al.) 2022 |
| Duloxetine lowered average joint pain more than placebo by 12 weeks “By 12 weeks, the average joint pain score was 0.82 points lower for patients who received duloxetine compared with those who received placebo” | Randomised phase III trial; not a graded recommendation (funded in part by Lilly USA) | Journal of Clinical Oncology (Henry et al.; supported by the US National Cancer Institute and in part by Lilly USA, the maker of duloxetine) 2018 |
| Exercise improved aromatase inhibitor joint pain in previously inactive women “Exercise led to improvement in AI-induced arthralgia in previously inactive breast cancer survivors.” | Randomised trial; not a graded recommendation | Journal of Clinical Oncology (Irwin et al.) 2015 |
| Acupuncture reduced joint pain at 6 weeks; clinical importance uncertain “resulted in a statistically significant reduction in joint pain at 6 weeks, although the observed improvement was of uncertain clinical importance.” | Randomised trial; not a graded recommendation | JAMA (Hershman et al.; funded by the US National Institutes of Health) 2018 |
| More than one third of women who switch may tolerate a second aromatase inhibitor “Of the 83 patients who chose to switch to the second AI, 38.6% continued the alternate AI for a median of 13.7 months.” | Exploratory analysis of a randomised trial; not graded (supported in part by Pfizer and Novartis grants) | Journal of Clinical Oncology (Henry et al.; supported by US National Institutes of Health grants and by grants from Pfizer and Novartis Pharma AG, the makers of exemestane and letrozole) 2012 |
| Paclitaxel aches are usually transient “The symptoms were usually transient, occurred two or three days after paclitaxel administration, and resolved within a few days.” | Regulatory label; not graded | Hospira, on DailyMed (US National Library of Medicine) 2026 |
| Steroids may reduce the tendency to develop paclitaxel aches “Steroids may reduce the tendency to develop myalgia and arthralgias.” | NCI PDQ summary; this statement is not graded | US National Cancer Institute 2025 |
| No standard prevention or treatment for the paclitaxel acute pain syndrome “have not yielded enough evidence to establish a standard practice.” | Cohort study; authors' statement, not graded | Journal of Clinical Oncology (Loprinzi et al.; supported in part by US Public Health Service grants) 2011 |
| Drug treatment of ibrutinib joint pain is anecdotal “Arthralgias can be adjunctively treated with pharmacotherapy, although evidence is anecdotal.” | Expert review; not graded | Hematology, American Society of Hematology Education Program (Lipsky and Lamanna; one author declares advisory roles and research support from makers of BTK inhibitors) 2020 |
| Ibrutinib cohort: a dose reduction alone relieved symptoms more often than a hold alone “Dose hold without dose reduction was successful in 14% (1/7) of patients, while dose reduction alone alleviated symptoms in 60% (9/15).” | Retrospective single-centre cohort; not graded | Clinical Lymphoma, Myeloma and Leukemia (Rhodes et al.; supported by a US training grant and a Conquer Cancer Foundation award; several authors declare consultancy or research funding from makers of BTK inhibitors) 2020 |
| Imatinib cramps: no definitive treatment “Other than symptomatic relief, there is no definitive treatment.” | Expert recommendation; not graded | Leukemia (Steegmann et al., for the European LeukemiaNet; authors declare honoraria and research funding from the makers of the drugs discussed) 2016 |
| Binimetinib, EU: keep the dose for a grade 3 rise without symptoms and ensure hydration “Binimetinib dose should be maintained and it should be” | Regulatory document; not graded | Pierre Fabre Médicament, on the European Medicines Agency website 2026 |
| Binimetinib, EU: monthly creatine kinase and creatinine for the first 6 months “CK and creatinine levels should be monitored monthly during the first 6 months of treatment and as clinically indicated.” | Regulatory document; not graded | Pierre Fabre Médicament, on the European Medicines Agency website 2026 |
| Cobimetinib, EU: no dose change at grade 3 or lower without symptoms “After rhabdomyolysis has been ruled out, Cotellic dosing does not need to be modified.” | Regulatory document; not graded | Roche Registration, on the European Medicines Agency website 2025 |
| Avutometinib with defactinib: monitoring schedule “Monitor CPK prior to the start of each cycle, on day 15 of the first four cycles, and as clinically indicated.” | Regulatory label; not graded | Verastem, on DailyMed (US National Library of Medicine) 2025 |
| Vimseltinib, EU: rises in creatine kinase had not led to rhabdomyolysis in clinical studies, which is not excluded “Although currently these elevations did not result in any cases of liver injury or rhabdomyolysis in clinical studies, this is not excluded since experience in this rare clinical condition is very limited.” | Regulatory document; not graded | Deciphera Pharmaceuticals (Netherlands), on the European Medicines Agency website 2026 |
| Vemurafenib, US: withhold for intolerable grade 2 or greater adverse reactions “Withhold ZELBORAF for NCI-CTCAE (v4.0) intolerable Grade 2 or greater adverse reactions.” | Regulatory label; not graded | Genentech, on DailyMed (US National Library of Medicine) 2026 |
| Encorafenib, US: its dose is not modified for a creatine kinase rise “Dose modification of BRAFTOVI when administered with binimetinib or with cetuximab is not recommended for new primary cutaneous malignancies; ocular events other than uveitis, iritis, and iridocyclitis; interstitial lung disease/pneumonitis; creatine phosphokinase (CPK) elevation; rhabdomyolysis; and venous thromboembolism.” | Regulatory label; not graded | Array BioPharma (Pfizer), on DailyMed (US National Library of Medicine) 2026 |
Shares Aromatase inhibitor, Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors).
Shares Binimetinib, Cobimetinib, Vemurafenib, Encorafenib.
Shares Aromatase inhibitor, Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors).
Shares Bone health on aromatase inhibitors, ovarian suppression and androgen deprivation therapy, Aromatase inhibitor, Anastrozole, Exemestane.
Shares Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors).
Shares Duloxetine, Taxanes (paclitaxel, docetaxel, nab-paclitaxel), Chronic pain in cancer survivors: assessment, non-opioid treatment first and careful opioid use, Chemotherapy nerve damage (peripheral neuropathy): assessment, dose changes and prevention.
Shares Binimetinib, Vemurafenib, Encorafenib.
Shares Anastrozole, Exemestane, Letrozole (and other aromatase inhibitors).